Newsletter no 4 2017

At Xintela, we continue to work intensively to achieve milestones. We now have full focus on the preparation of the GMP (Good Manufacturing Practice) production of our stem cells and preparing for clinical trials in both horses and humans. At the end of May, we announced the signing of a Memorandum of Understanding agreement with […]

Xintela recruits Liselotte Theorell as Director Product Development and Quality Management

Xintela AB (publ) announces that the company has recruited Liselotte Theorell as Director Product Development and Quality Management. The recruitment is an important step towards the production of stem cells under GMP (Good Manufacturing Practice) for upcoming clinical studies. “Liselotte is one of few persons in Sweden who possess such extensive competence in quality management […]

Xintela signs memorandum of understanding with CO.DON

Xintela AB (publ) announces today that the company has signed a non-binding Memorandum of Understanding with the leading European cell therapy company, CO.DON. The parties intend to collaborate on the development of Xintela’s quality markers for CO.DON’s next cell-based product and for the co- development of Xintela’s stem cell product for the treatment of osteoarthritis. […]

Newsletter no 3 2017

Table of contents:Interview with Thomas Areschoug, newly recruited and responsible for Xintela’s Business DevelopmentChanges in Xintela’s R&D TeamMeeting with the European Medical AgencyXintela is participating in the International Cartilage Repair Society Heritage Summit 2017 and start-up event in May/June

Keld Søndergaard nominated as new board member

The Board of Xintela AB (publ) announces that Keld Søndergaard has been nominated for election as a new member of the Board at the annual general meeting on the 18th of May 2017. Also proposed for re-election are Greg Batcheller, Karin Wingstrand, Sven Kili and Claes Post. The proposal is supported by shareholders who represent […]

Newsletter no 2 2017

A word from the CEO The intense period in Xintela operations has continued and positively so. Previously, we reported on the good progress of both our regenerative medicine and cancer projects, which continue to develop quickly. We are currently focusing on starting stem cell production according to Good Manufacturing Practice (GMP), as well as obtaining […]

Xintela strengthens business development and reorganizes

Xintela announces today that Thomas Areschoug has been recruited to the business development team as Business Development Manager. In addition, the company is reorganizing in order to develop its projects more efficiently. – We are very pleased to have Thomas Areschoug join the team. His broad international network and experience is exactly what Xintela now […]

Newsletter no 1 2017

Table of contents:The subscription period for shares supported by warrants has startedInterview with Dr. Lisa Fortier regarding the horse studyUpdate on Xintela´s projectsInterview with Greg BatchellerXintela in social media

Xintela reports positive preclinical results in cancer project

Xintela AB (publ) today announces an update of the company’s projects in regenerative medicine and cancer. All projects are developing in a positive way. New results from the cancer project show that Xintela’s targeting antibody kills glioblastoma cells both in cell studies and in an animal model. Significant progress in the treatment of the brain […]